Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2024-06-21 00:00:00 ET · period of report 2024-06-20 · accession 0001104659-24-073941 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-21 | 2024-06-20 | APRE | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +1,045 | 9,184 | +13% | $0 |
| D | 2024-06-21 | 2024-06-20 | APRE | HENNEMAN JOHN B III | Dir | A - Grant | $0.00 | +4,185 | 4,185 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-20 | A | A | 1,045 | $0.00 | 9,184 | D | — | — | (F1) These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| 2 | Derivative | Stock Options (Right to Buy) | 2024-06-20 | A | A | 4,185 | $0.00 | 4,185 | D | $4.07 · — to 2034-06-20 | 4,185 Common Stock | (F2) The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |